Abstract: Derivatives of purine, adenine, guanine, and 2,6-diaminopurine linked to the azanonaborane (B 8 N cluster) have been prepared, for possible use as powerful agents for boron neutron capture therapy (BNCT). The synthesis was carried out via a ligand exchange reaction. The exo-NH 2 R group of the azanonaborane of the type [(RH 2 N)B 8 H 11 NHR] can be exchanged by one hetero-nitrogen atom of the pyrimidine ring, and except for guanine, also by an N atom of the imidazole ring. The identity of the products was confirmed by NMR, elemental analysis, IR, and mass spectrometry. No reaction was found to occur with caffeine and theophylline under the same reaction conditions.
Introduction
The use of boron compounds for the boron neutron capture therapy (BNCT) of cancer depends upon the capture of thermal neutrons by boron-10 ( 10 B) nuclei that have been selectively delivered to tumor cells [1] [2] [3] . Following this capture, the resulting activated 11 B nucleus undergoes prompt fission. The energy of the particles emitted is very large by nuclear standards, which provides the basis for attempting to destroy malignant cells selectively without affecting surrounding normal cells [1] [2] [3] . In order for BNCT to succeed, it is necessary to continue in discovering new boron delivery agents. Many different substituted boron clusters, predominantly derivatives of closo-B 12 H 12 2-, closo-B 10 H 10 2-, and the three isomeric dicarba-closo-dodecaborane(12) species [4] , were functionalized and connected to organic molecules [1] [2] [3] 5] . The most promising approaches for this task involve porphyrins, monoclonal antibodies, nucleosides, amino acids, and lipids.
It is known that pyrimidine derivatives are taken up more in cancer cells than in normal cells. The utility of analogues of purine nucleosides as drugs is well documented [6, 7] . Modified nucleosides and nucleic acid bases have been the subject of many studies due to their potential activity as enzyme inhibitors resulting in antitumor [8] and antiviral activity [9] . Early work focused on the development and synthesis of boron containing purine and pyrimidine bases [10] [11] [12] [13] [14] [15] [16] [17] . In some cases, the boron atom was placed within the purine or pyrimidine ring flanked by two nitrogen atoms [13] . A number of these compounds proved to be too toxic or hydrolytically unstable and, therefore, were of little use as potential BNCT agents [18] .
In an effort to discover new and effective BNCT agents for the treatment of cancer, we recently presented the azanonaborane (B 8 N, Fig. 1 ) cluster as a new candidate for application in BNCT [19] [20] [21] [22] [23] [24] [25] [26] . For some years, we have been working on the synthesis and structural and biological evaluation of azanonaborane by incorporating polar functional groups [19] [20] [21] [22] , porphyrins [23, 24] , sugars [25] , or heterocyclic bases [26] with the hope of achieving properties suitable for BNCT: high and differential accumulation of boron, by using compounds with low toxicity, high boron content, and moieties suitable for physiological targeting. The in vitro cytotoxicity of various functionalized azanonaborane clusters was reported [19] [20] [21] [22] [23] [24] [25] [26] . The cluster itself appears not to have a high toxic potential [19] [20] [21] [22] [23] [24] [25] [26] . Among a large number of molecules examined, the B 8 N containing sugars [25] displayed good cell survival over a wide range of boron concentrations even at higher boron concentration (300 µg boron mL -1 , corresponding to a compound concentration of 3.5 mM). As part of our work on the effects of these modifications on the B 8 N cluster, we describe in the present paper the synthesis and characterization of new purine and purine derivatives (e.g. 2,6-diaminopurine, 6-aminopurine (adenine), guanine, caffeine, and theophylline), containing the B 8 N cluster, as a new boron containing heterocyclic moieties for BNCT.
Experimental Procedures
Purine, 2,6-diaminopurine, 6-aminopurine (adenine), guanine, caffeine, theophyllene and dry solvents were commercially available from chemical companies and used without further purification. Dimethylsulfide arachno nonaborane cluster B 9 H 13 (SMe 2 ) and azanonaborane cluster of the type [(iPrH 2 N)B 8 H 11 NHiPr] were prepared by literature methods [27, 28] . All reactions were carried out under dry nitrogen but subsequent manipulatory and separatory procedures were carried out in air. Preparative thin layer chromatography (TLC) was carried out using 0.75 mm layers of silica gel G (Merck, GF 254 Only the signal with the highest intensity of the boron isotopic pattern is listed. Partial charges were calculated using the Extended Hückel package of Chem3D Pro 8.
General procedure for the synthesis of compounds 2-8
A solution of B 8 N cluster 1 (1 mmol) was dissolved in 10 mL anhydrous benzene, and the appropriate purine or purine derivatives {2,6-diaminopurine, 6-aminopurine (adenine), guanine, caffeine, theophylline} for the ligand exchange reaction were added (1.2 mmol). After heating the solution to reflux for two hours the solvent was evaporated under vacuum. The residue, consisting of the crude azanonaborane product, was then purified by repeated thin layer chromatography on silica gel using dichloromethane and THF (1:1) or THF as the liquid phase. Criteria of purity and identity were multinuclear NMR spectra consistent with the molecular structure, together with corresponding molecular ions in the mass spectrum, and with microanalysis of all resulting compounds. 
Compound 2

Compound 3
Yield (0.03 g, 17%) as a deep yellow solid; R f = 0.71 (THF/CH 2 Cl 2 1:1); IR ν max (KBr disc)/cm -1 2988w (CH), 2528s (BH), 1626s (C=C), 1591s (NH), 1452s (BN), 
Results and Discussion
The B 8 N cluster [(RH 2 N)B 8 H 11 NHR] can be directly synthesized from the reaction of one mole of dimethylsulfide-arachno-nonaborane [B 9 H 13 (SMe 2 )] with three moles of primary amino ligand (RNH 2 ) in refluxing benzene [27, 28] . The [B 9 H 13 (SMe 2 )] cluster is obtained from decaborane (14) and, thus, can be obtained in boron-10-enriched form if desired. As we were primarily interested whether the synthesis of purine derivatives is possible, we used the natural isotope distribution of boron. The exo amine ligand (RNH 2 ) can be readily replaced with other primary or secondary amines [29] . Aliphatic amines can be replaced with pyridine [30, 31] or imidazole [26] derivatives. In line with these results, we found it is possible to exchange the RNH 2 group with purine or purine derivatives to synthesize new azanonaborane clusters containing a purine moiety. The exchange reaction of azanonaborane cluster of the type [(iPrH 2 N)B 8 H 11 NHiPr] 1 with purine in 1:1.2 ratio in refluxing benzene for two hours gave the monosubstituted 2 and the bis-substituted 3 in 30% and 17% yield as yellow solid substances, respectively, with purine as a base (Scheme 1). The formation of compound 3 containing two clusters was attributed to the exchange reaction on both hetero rings (pyrimidine and imidazole rings) which gives the chance to obtain compound containing two B 8 N units. Also, the interaction of adenine and 2,6-diaminopurine with the B 8 N cluster gave 4 (27%) and 5 (15%), and 6 (23%) and 7 (16%), respectively, as mono-and bis-substituted products (Scheme 1). However, under the same reaction conditions where adenine and 2,6-diaminopurine, gave both mono-and bis-substituted products, guanine formed only the mono-substituted product 8 (15%) as faint yellow solid substance. There is no obvious reason for the different reactivity of guanine in comparison to the other bases tested. Extended Hückel calculations gave charges for the N atom at position 7 in the imidazole ring which ranged from -0.465 to -0.473 for cases where a reaction was observed. The values for the two tautomers of guanine (-0.467 for the keto form, -0.470 for the OH form) were not different. Previously, we had shown that imidazole derivatives could react; only in the case of 2-nitroimidazole, no reaction was observed. In this case, the electron-withdrawing property of the nitro group changed the charge on the imino N atom from -0.435 to -0.403. No reaction was observed when using caffeine or theophylline under the same reaction conditions. As the N-atom 1 is methylated in both cases, and the keto function at C-6 is present as in guanine, the lack of reactivity might have the same reason as the and NH 2 groups of the exo-ligand (iPrH 2 N) diagnostically resonate at ca. +1.3, +2.7, and +4 ppm, respectively. The disappearance of these signals and the appearance of new signals corresponding to the purine moiety of compounds 2-8 indicate the formation of boronated purine (see for example Fig. 2 ). Also, 13 C NMR spectra indicate the appearance of new signals corresponding to the organic moiety of each compound (Fig. 3) .
The vibrational frequency of B-H band ν(B-H) or the B-B band ν(B-B) was not found to be sensitive to the connection of the purine and purine derivatives. B 8 N cluster unit attached to the purine moiety (Fig. 4) . For the other compounds, the mass spectra show the equivalent isotope patterns. The color of the compounds 2-8 might be due to the electronic interaction between the boron cluster unit and the bonded pyrimidine unit, as has been found for the monopyridine or bipyridine compounds [30, 31] . This phenomenon may be related to that found for other borane pyridine complexes, particularly those of the {6,9-L2-arachno-B 10 H 12 } constitution [32] .
Conclusions
The compounds described here represent a novel class of B 8 N cluster containing purine derivatives that were synthesized by one step reactions. These compounds represent the first examples of purine derivatives containing the azanonaborane cluster. The ligand exchange reaction was found to be a suitable route to synthesize B 8 N cluster containing purine, adenine, guanine and 2,6-diaminopurine. Purine, adenine, or 2,6-diaminopurine, but not guanine, reacted with the cluster in a ratio 1:1.2, affording compounds containing two B 8 N cluster units, one at the N1of the pyrimidine unit and one at the N7 of the imidazole unit. 
